Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management.

IF 2.8 3区医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

Frontiers in Cardiovascular Medicine Pub Date : 2025-03-20 eCollection Date: 2025-01-01 DOI:10.3389/fcvm.2025.1546515

Wang Dui, Zhao Xiaobin, Zhang Haifeng, Dang Lijuan, Huang Wenhui, Zhang Zhengfeng, Song Jinling

{"title":"Harnessing RNA therapeutics: novel approaches and emerging strategies for cardiovascular disease management.","authors":"Wang Dui, Zhao Xiaobin, Zhang Haifeng, Dang Lijuan, Huang Wenhui, Zhang Zhengfeng, Song Jinling","doi":"10.3389/fcvm.2025.1546515","DOIUrl":null,"url":null,"abstract":"<p><p>RNA therapeutics are emerging as a promising approach for cardiovascular diseases (CVDs) management, offering targeted gene regulation through modalities like mRNA, siRNA, and miRNA. In recent years, researchers have conducted a lot of research on the application of RNA therapeutics technology in the treatment of CVDs. Despite hurdles in off-target effects and immune responses, the clinical trial outcomes are encouraging. This review synthesizes the current progress in RNA therapeutics for CVDs, examining their mechanisms, advantages, and challenges in delivery and safety. We highlight the potential of personalized medicine, combination artificial intelligence (AI) and bioinformatics in advancing RNA therapeutics. The future of RNA therapeutics in CVDs is poised for significant impact, necessitating continued research and interdisciplinary collaboration to optimize these treatments and ensure patient safety and efficacy.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"12 ","pages":"1546515"},"PeriodicalIF":2.8000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11965680/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Cardiovascular Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fcvm.2025.1546515","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 0

Abstract

RNA therapeutics are emerging as a promising approach for cardiovascular diseases (CVDs) management, offering targeted gene regulation through modalities like mRNA, siRNA, and miRNA. In recent years, researchers have conducted a lot of research on the application of RNA therapeutics technology in the treatment of CVDs. Despite hurdles in off-target effects and immune responses, the clinical trial outcomes are encouraging. This review synthesizes the current progress in RNA therapeutics for CVDs, examining their mechanisms, advantages, and challenges in delivery and safety. We highlight the potential of personalized medicine, combination artificial intelligence (AI) and bioinformatics in advancing RNA therapeutics. The future of RNA therapeutics in CVDs is poised for significant impact, necessitating continued research and interdisciplinary collaboration to optimize these treatments and ensure patient safety and efficacy.

查看原文本刊更多论文

利用 RNA 疗法：治疗心血管疾病的新方法和新策略。

RNA 疗法通过 mRNA、siRNA 和 miRNA 等方式对基因进行靶向调控，正在成为治疗心血管疾病（CVDs）的一种前景广阔的方法。近年来，研究人员对 RNA 治疗技术在心血管疾病治疗中的应用进行了大量研究。尽管存在脱靶效应和免疫反应等障碍，但临床试验结果令人鼓舞。这篇综述总结了目前 RNA 疗法在治疗心血管疾病方面取得的进展，探讨了其机制、优势以及在给药和安全性方面面临的挑战。我们强调了个性化医疗、人工智能（AI）和生物信息学在推进 RNA 疗法方面的潜力。RNA 疗法在心血管疾病领域的未来将产生重大影响，因此有必要继续开展研究和跨学科合作，以优化这些疗法并确保患者的安全和疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Cardiovascular Medicine Medicine-Cardiology and Cardiovascular Medicine

CiteScore

3.80

自引率

11.10%

发文量

3529

审稿时长

14 weeks

期刊介绍： Frontiers? Which frontiers? Where exactly are the frontiers of cardiovascular medicine? And who should be defining these frontiers? At Frontiers in Cardiovascular Medicine we believe it is worth being curious to foresee and explore beyond the current frontiers. In other words, we would like, through the articles published by our community journal Frontiers in Cardiovascular Medicine, to anticipate the future of cardiovascular medicine, and thus better prevent cardiovascular disorders and improve therapeutic options and outcomes of our patients.